Search
Cancer Immunotherapy Toxicity Evaluation (CITE) Program
UCSF Health’s new Cancer Immunotherapy Toxicity Evaluation (CITE) Program is a valuable resource for both patient care and provider consults.A Novel Approach Towards a Vaccine for Relapsing Acute Myeloid Leukemia: Q&A with Dr. Karin Gaensler
There is a major clinical unmet need for effective and safe therapies to increase progression-free and overall survival in older individuals with leukemia whose prognosis is grim.Robotically Assisted, Completely Minimally Invasive Whipple Surgery: Case Study With Video
Since performing San Francisco’s first pure robotically assisted Whipple procedure in 2022, UCSF surgeons continue to be on the forefront of this technology, regularly performing robotic Whipple surgeries (pancreatoduodenectomies) on select patients.UCSF Health Performs 150th Robotic Focal HIFU Procedure
UCSF is West Coast leader for the innovative, minimally invasive treatment for prostate cancer patients.New Research on Optimizing UC Management Through Patient-Centered Tofacitinib Dosing
Tofacitinib is effective for managing ulcerative colitis (UC) and is linked to sustained steroid-free remission. The product label recommends dose de-escalation after eight or 16 weeks, but is this best for patients?Deadly Dust: Engineered Stone Is Making California Workers Sick
Workers making artificial-stone slabs for the most popular type of countertops sold in the United States are developing a potentially deadly, irreversible lung disease from tiny particles of toxic dust, researchers from UC San Francisco and UCLA found...Millions of Long-Term Smokers Have Lung Disease that Defies Diagnosis
Millions of Americans with tobacco-related lung disease have symptoms that do not fit any existing tobacco-related disease criteria – including the most common of those, chronic obstructive pulmonary disease (COPD)...Novel Intraoperative Prostate Cancer Imaging Method Reveals Previously Undetectable Disease
UCSF researchers led the first-in-human study of a novel near-infrared fluorescence imaging agent that targets prostate-specific membrane antigen (PSMA).Neuroendovascular Surgery
The newly formed Neuroendovascular Surgery program at UCSF offers accessible, coordinated care for even the most complex vascular disorders of the central nervous system.UCSF Health Cancer Services Earns National Accreditation from the Commission on Cancer of the American College of Surgeons
The UCSF cancer program has been continuously accredited by the CoC since 1933, demonstrating its commitment to the best outcomes possible for its cancer patients.Does Hydrocortisone Improve Treatment of Septic Shock?
Sepsis is a global health priority affecting 55 million patients worldwide and causing 11 million deaths annually.Acute Kidney Injury is not Associated with Worsening Kidney Function in Patients with Chronic Kidney Disease
A UC San Francisco (UCSF)-led study of patients with chronic kidney disease (CKD) has found that mild-to-moderate acute kidney injury (AKI) did not predict worsening of kidney function after taking into account differences in pre-existing health.UCSF Among First in U.S. to Receive New Surgery Designation from the American College of Surgeons
UC San Francisco Medical Center (UCSF) is among just four hospitals in the U.S. to be verified as part of the American College of Surgeons (ACS) Vascular Verification Program (Vascular-VP)...Aggressive Blood Pressure Control May Prevent Common Heart Condition
Heart conduction disorders can often lead to serious or fatal complications including complete heart block or heart failure.Can Artificial Intelligence Reduce Invasive Testing and Improve Cardiac Diagnostics?
Coronary heart disease is the leading cause of adult death worldwide.New Hypoparathyroidism Guidelines and Emerging PTH Replacement Therapies for Improved Patient Outcomes
New guidelines from the Second International Workshop on the Evaluation and Management of Hypoparathyroidism provide clinicians with the latest evidence-based recommendations for the prevention, diagnosis and management of this rare disease.Transgender Women Benefit from Prostate Cancer Screenings
Transgender women keep their prostates after gender-affirming surgery, and as a result are still at risk for prostate cancer.Renowned Urologic Specialist to Lead UCSF Urology Program
Benjamin N. Breyer, MD, MAS, FACS, a renowned leader in urology and urological surgery, has been appointed chair of the UCSF Department of Urology.Low-Risk Differentiated Thyroid Cancer Case Studies: Patient-Centered Approaches to Treatment
A 2022 UCSF study found that, since publication of the 2015 American Thyroid Association (ATA) guidelines, surgeons nationwide are performing more thyroid lobectomies for low-risk differentiated thyroid cancer (DTC) proportional to other thyroid surgeries for the condition.Focused Ultrasound Stops Tremors in Patients with Movement Disorders: UCSF Case Studies
High-intensity focused ultrasound (HIFU) is an incision-free, minimally invasive outpatient procedure during which MRI-guided ultrasound is directed at the ventral intermediate (VIM) nucleus of the thalamus.UCSF Internal Medicine Specialist Celebrated for Diabetes Epidemiology Research
Alka M. Kanaya, MD, UC San Francisco primary care physician and researcher, has been honored with the 2023 Kelly West Award for Outstanding Achievement in Epidemiology from the American Diabetes Association (ADA).Can Reducing Insulin Resistance Minimize Severe Asthma Symptoms?
UCSF researchers led a study that found insulin resistance (IR) is common in patients with severe asthma and is associated with lung function impairment and suboptimal responses to asthma medications.Scientists Discover a Deadly Brain Cancer’s Hidden Weakness
The difficult-to-treat brain cancer glioblastoma steals a person’s mental faculties as it spreads, yet the tumor’s insidious ability to infiltrate distant networks in the brain could also prove its undoing.UCSF Surgical Oncologists Providing New Treatment Options for Patients with Metastatic Gastrointestinal Cancers
UCSF Health’s surgical oncology team is a Bay Area leader in an innovative chemotherapy infusion pump used to treat patients with widely metastatic colorectal and bile duct cancers that have spread to the liver and are no longer considered operable.